

IMAGION BIOSYSTEMS LIMITED

ASX: IBX

2 July 2024

CHANGE OF REGISTERED OFFICE AND PRINCIPAL PLACE OF BUSINESS ADDRESS

MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, makes this announcement to advise that effective from 1 July 2024, the Registered Office and Principal Place of Business will change to:

Registered Office and Principal Place of Business

Address: Level 4
96-100 Albert Road
South Melbourne VIC 3205

Phone: +61 3 9692 7222

Fax: +61 2 9956 7355

— ENDS —

About Imagion Biosystems

Established in 2017 and headquartered in the San Diego, California, US, Imagion Biosystems is an ASX-listed company dedicated to developing innovative medical imaging technologies for various cancer types. Imagion Biosystems is advancing clinical development of its MagSense® platform technology to revolutionize cancer diagnosis, introducing molecular imaging to MRI. The Company's lead program has demonstrated its innovative technology embodied in MagSense® HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients diagnosed with HER2+ breast cancer. Imagion Biosystems' MagSense® pipeline includes prostate cancer, ovarian cancer, pancreatic cancer, and brain cancer programs.

For more information, visit <https://imaginationbiosystems.com/investor-hub/>

Authorisation & Additional information

This announcement was authorised by the Board of Imagion Biosystems Limited.

